🔗 Share this article Users Stopping Weight-Loss Injections Put On Weight at a Quadrupled Rate Compared to People Using Diet and Exercise Weight management involves long-term strategies. Fresh analysis indicates that patients who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who end conventional diet and exercise plans. Research printed in a prominent medical journal points out that while overweight people often shed about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation. "People purchasing such drugs should be aware of the danger of rapid weight regain when the medication ends," cautioned expert Dr. Susan Jebb. This pace of recovery means a reversion to original mass within about one and a half years. Analyzing Approaches The research, which reviewed dozens of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting. Scientists point out that individuals who shed pounds through dieting typically experience a slower weight regain—perhaps 100 grams monthly—post-intervention. Understanding the Rapid Regain Nutrition scientists believe the mechanism of the jabs explains the heightened weight return. These medications imitate a natural hormone called glucagon-like peptide-1, which moderates appetite. "Sustained high doses of the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert. "Discontinuation of this hormone supplement results in appetite is no longer kept in check, making overeating a significant risk." An Ongoing Issue? Health authorities advise the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications. Many experts say that, considering the high risk of weight regain, the treatment should be considered ongoing. This view is supported by drug manufacturers, who state that the results "emphasize the chronic character of excess weight," akin to managing diseases like hypertension. Patient Experiences Users who have come off the medication explain a intense resurgence of cravings. "It was like a trigger flipping and you become starving," recalled a patient. The struggle is worsened if patients have not established sustainable lifestyle or habit modifications during therapy. Growing Use Figures indicate that a significant number of adults in the UK have used these injections in the past year, with demand remaining high. Adoption is higher among women compared to males. The middle-aged age group shows the highest usage rates. Many obtain the medications through private prescriptions rather than public health services. Finally, clinicians caution that while these medications are potent agents for weight loss, they are not a magic solution and lasting health benefits hinges on ongoing behavioural support.
Weight management involves long-term strategies. Fresh analysis indicates that patients who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who end conventional diet and exercise plans. Research printed in a prominent medical journal points out that while overweight people often shed about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation. "People purchasing such drugs should be aware of the danger of rapid weight regain when the medication ends," cautioned expert Dr. Susan Jebb. This pace of recovery means a reversion to original mass within about one and a half years. Analyzing Approaches The research, which reviewed dozens of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting. Scientists point out that individuals who shed pounds through dieting typically experience a slower weight regain—perhaps 100 grams monthly—post-intervention. Understanding the Rapid Regain Nutrition scientists believe the mechanism of the jabs explains the heightened weight return. These medications imitate a natural hormone called glucagon-like peptide-1, which moderates appetite. "Sustained high doses of the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and could reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition expert. "Discontinuation of this hormone supplement results in appetite is no longer kept in check, making overeating a significant risk." An Ongoing Issue? Health authorities advise the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications. Many experts say that, considering the high risk of weight regain, the treatment should be considered ongoing. This view is supported by drug manufacturers, who state that the results "emphasize the chronic character of excess weight," akin to managing diseases like hypertension. Patient Experiences Users who have come off the medication explain a intense resurgence of cravings. "It was like a trigger flipping and you become starving," recalled a patient. The struggle is worsened if patients have not established sustainable lifestyle or habit modifications during therapy. Growing Use Figures indicate that a significant number of adults in the UK have used these injections in the past year, with demand remaining high. Adoption is higher among women compared to males. The middle-aged age group shows the highest usage rates. Many obtain the medications through private prescriptions rather than public health services. Finally, clinicians caution that while these medications are potent agents for weight loss, they are not a magic solution and lasting health benefits hinges on ongoing behavioural support.